-

08:03:41 PM

LIVE Real Time UTHR Stock Market News

UTHR - United Therapeutics Corp

04/19/21 6:00 AM

Nasdaq : UTHR

United Therapeutics Announces Submission of Tyvaso DPI(TM) New Drug Application to FDA

United Therapeutics Corporation (Nasdaq: UTHR) today announced the submission of a new drug application ( NDA) to the U.S. Food and Drug Administration ( FDA) for Tyvaso DPI(TM), a novel dry powder inhalation

RHEA-AI

positive

04/01/21 6:00 AM

Nasdaq : UTHR

United Therapeutics Announces FDA Approval and Launch of Tyvaso(R) for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

United Therapeutics Corporation (Nasdaq: UTHR) today announced that the U.S. Food and Drug Administration (FDA) has approved Tyvaso (R) (treprostinil) Inhalation Solution for the treatment of patients with pulmonary

RHEA-AI

positive

03/24/21 6:00 AM

Nasdaq : UTHR

United Therapeutics Corporation To Present At The 10th Annual J.P. Morgan Napa Valley Forum

United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Gil Golden, Executive Vice President and Chief Medical Officer of United Therapeutics, will provide an overview and update on the company's

RHEA-AI

neutral

03/09/21 6:00 AM

Nasdaq : UTHR

United Therapeutics Corporation To Present At The Oppenheimer 31st Annual Healthcare Conference

United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt, Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business

RHEA-AI

neutral

02/24/21 4:30 PM

Nasdaq : UTHR

United Therapeutics Corporation To Present At The 41st Annual Cowen Health Care Conference

United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. Michael Benkowitz, President and Chief Operating Officer of United Therapeutics, will provide an overview and update on the company's business

RHEA-AI

neutral

02/24/21 6:00 AM

Nasdaq : UTHR

United Therapeutics Corporation Reports Fourth Quarter And Full Year 2020 Financial Results

United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the fourth quarter and year ended December 31, 2020. Full year net revenue rose to $1,483 million, as U.S. patients being

RHEA-AI

neutral

02/17/21 6:00 AM

Nasdaq : UTHR

United Therapeutics Corporation To Report Fourth Quarter And Full Year 2020 Financial Results Before The Market Opens On Wednesday, February 24, 2021

United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2020 financial results before the market opens on Wednesday, February 24, 2021.United Therapeutics

RHEA-AI

neutral

02/10/21 6:00 AM

Nasdaq : UTHR

United Therapeutics Announces Commercial Launch Of The Remunity(R) Pump For Remodulin(R)

United Therapeutics Corporation (Nasdaq: UTHR) announced today that it has launched commercial sales of the innovative Remunity (R) Pump for Remodulin (R) for patients with pulmonary arterial hypertension (PAH). "We are

RHEA-AI

positive

01/28/21 6:00 AM

Nasdaq : UTHR

United Therapeutics Announces BREEZE Study of Investigational Tyvaso DPI(TM) Meets Primary Objective

United Therapeutics Corporation (Nasdaq: UTHR) announced today that that the BREEZE study of Tyvaso DPI (inhaled treprostinil) met its primary objective of demonstrating safety and tolerability in patients with

RHEA-AI

neutral

01/13/21 5:01 PM

Nasdaq : UTHR

United Therapeutics Announces New England Journal of Medicine Publication of the INCREASE Study Evaluating Tyvaso(R) in Pulmonary Hypertension Associated with Interstitial Lung Disease

United Therapeutics Corporation (Nasdaq: UTHR) today announced that results from the INCREASE clinical study of Tyvaso (R) (treprostinil) Inhalation Solution for the treatment of pulmonary hypertension associated with

RHEA-AI

neutral